Results 141 to 150 of about 13,805 (198)

Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model. [PDF]

Heliyon
Bellaye PS, Dias AM, Vrigneaud JM, Bouchard A, Moreau M, Petitot C, Bernhard C, Claron M, Froidurot L, Morgand V, Guillemin M, Monterrat M, Mirjolet C, Garrido C, Kohli E, Collin B.   +15 more
europepmc   +1 more source

Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence. [PDF]

Eur J Nucl Med Mol Imaging
Dieudonné A, Bailly C, Cachin F, Edet-Sanson A, Kraeber-Bodéré F, Hapdey S, Merlin C, Robin P, Salaun PY, Schwartz P, Tonnelet D, Vera P, Courbon F, Carlier T.   +13 more
europepmc   +1 more source

Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response. [PDF]

Front Immunol
Yang Y, Vedvyas Y, Alcaina Y, Son JY, Min IM, Jin MM.   +5 more
europepmc   +1 more source

Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands. [PDF]

Pharmaceuticals (Basel)
de Roode KE, Joosten L, Behe M.
europepmc   +1 more source

Autophagy inhibition improves the targeted radionuclide therapy efficacy of ¹³¹I-FAP-2286 in pancreatic cancer xenografts. [PDF]

J Transl Med
Liu X, Li D, Ma T, Luo X, Peng Y, Wang T, Zuo C, Cai J.   +7 more
europepmc   +1 more source

Dosimetry of alpha-emitting radionuclides for targeted radionuclide therapy

Targeted radionuclide therapy (TRT) is a nuclear medicine-based cancer treatment technique that consists in coupling a radionuclide with a carrier molecule able to specifically target cancer cells. In this context, the radionuclides commonly used in clinic are mainly β− emitters (177Lu, 131I, 90Y), although an α-emitter (223Ra) has been recently ...
openaire   +1 more source

Prospective phase II trial of [⁶⁸Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy. [PDF]

EJNMMI Res
Azam A, Kurbegovic S, Carlsen EA, Andersen TL, Larsen VA, Law I, Skjøth-Rasmussen J, Kjaer A.   +7 more
europepmc   +1 more source

Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy. [PDF]

Front Immunol
Adhikarla V, Awuah D, Caserta E, Minnix M, Kuznetsov M, Krishnan A, Wong JYC, Shively JE, Wang X, Pichiorri F, Rockne RC.   +10 more
europepmc   +1 more source

A Monte Carlo study comparing dead-time losses of a gamma camera between tungsten functional paper and lead sheet for dosimetry in targeted radionuclide therapy with Lu-177. [PDF]

Ann Nucl Med
Nakanishi K, Fujita N, Iwanaga H, Asano Y, Abe S, Nishii R, Kato K.   +6 more
europepmc   +1 more source